AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 16 2023 - 7:00AM
Business Wire
- Industry veteran brings more than 25 years of
global commercial leadership and cell therapy expertise to AlloVir
to build out company's commercial strategy and capabilities -
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell
immunotherapy company, today announced the appointment of Cintia
Piccina, PharmD, MBA, as the company’s Chief Commercial Officer,
effective June 12, 2023. Ms. Piccina will drive the global
commercialization strategy for AlloVir, with a focus on its lead
product, posoleucel, and be responsible for building a commercial
team in anticipation of a 2025 launch.
“Cintia is an accomplished executive with a track record of
successful cell therapy and oncology product launches and product
growth. She will be instrumental in building and driving AlloVir’s
capabilities, particularly in support of our lead investigational
product, posoleucel, a multi-virus specific T cell therapy
targeting six devasting viral infections,” said Diana Brainard, MD,
Chief Executive Officer, AlloVir. “Her proven leadership in
building commercial strategies, talent, and teams, will be critical
to AlloVir as we advance toward data readouts anticipated next year
for our three registrational trials currently underway.”
Ms. Piccina is a seasoned leader with over 25 years of
experience in the pharmaceutical industry. Most recently, she
served as Chief Commercial Officer of Adaptimmune Therapeutics,
where she built commercialization capabilities and a team to
support the launch of the company’s first commercial product, which
could be the first engineered TCR T cell therapy approved for the
treatment of solid tumors. Prior to this, she was the Head of
Commercial and SVP Commercial Oncology at 2seventy bio and U.S.
General Manager at bluebird bio, where she led the launch of the
first cell therapy product in multiple myeloma, Abecma
(idecabtagene vicleucel). Before this, Ms. Piccina spent more than
two decades at Novartis, first in Brazil and then in the U.S.,
where she held a series of commercial, marketing and sales roles
across multiple therapeutic areas including oncology, and in her
final role she was VP, Global Oncology Cell and Gene Strategy &
Program Management Office, for Kymriah and the CAR-T pipeline,
leading the cross-functional leadership teams for business
(marketing, medical affairs, market access), manufacturing, and
pipeline. Ms. Piccina holds a Doctorate in Pharmacy and
Biochemistry from the University of Sao Paulo, Brazil, and an MBA
from the Escola Superior de Propaganda e Marketing, Sao Paulo,
Brazil.
“AlloVir has the opportunity to improve outcomes for transplant
patients given the potential of posoleucel to prevent or treat
common serious viral diseases in this population for whom limited,
or no effective options currently exist,” said Cintia Piccina,
PharmD, MBA, Chief Commercial Officer, AlloVir. “I am impressed by
the exceptional foundational science that AlloVir is built upon and
thrilled to be a part of this innovative and experienced team
working together to realize the full potential of the VST platform
and advance therapeutics to help patients with high unmet
need.”
About AlloVir
AlloVir is a leading late-clinical stage, cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding AlloVir’s development and regulatory status of our
product candidates, the planned conduct of its preclinical studies,
and clinical trials and its prospects for success in those studies
and trials, and its strategy, business plans and focus. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties, and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those related to AlloVir’s financial results, the
timing for the initiation and successful completion of AlloVir’s
clinical trials of its product candidates, whether and when, if at
all, AlloVir’s product candidates will receive approval from the
U.S. Food and Drug Administration (FDA), or other foreign
regulatory authorities, competition from other biopharmaceutical
companies, the impact of the COVID-19 pandemic on AlloVir’s product
development plans, supply chain, and business operations and other
risks identified in AlloVir’s SEC filings. AlloVir cautions you not
to place undue reliance on any forward-looking statements, which
speak only as of the date they are made. AlloVir disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions, or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent AlloVir’s views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent
date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005163/en/
Media and Investor: ir@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jun 2024 to Jul 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jul 2023 to Jul 2024